BioAtla Investor Presentation Deck

BioAtla® is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABS) Proprietary technology Broad applicability in solid tumors Increases therapeutic bicatla window Two Phase 2 CAB-ADCs Interim BA3011 Phase 2 data supports advancing to registration studies in multiple sarcoma and NSCLC indications Diversified pipeline Near-term clinical readouts for multiple indications Strategic optionality Strong cash position $202.3MM (2022) with runway into 2H24 Sufficient through key clinical milestones BioAtla| Overview 3

View entire presentation